OmniAb, Inc. (OABI)
Market Cap | 605.54M |
Revenue (ttm) | 34.16M |
Net Income (ttm) | -50.62M |
Shares Out | 116.86M |
EPS (ttm) | -0.51 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 704,280 |
Open | 5.24 |
Previous Close | 5.19 |
Day's Range | 5.16 - 5.39 |
52-Week Range | 3.14 - 6.72 |
Beta | n/a |
Analysts | Strong Buy |
Price Target | 9.20 (+70.69%) |
Earnings Date | Mar 20, 2024 |
About OABI
OmniAb, Inc., a biotechnology company, engages in the provision of therapeutic antibody discovery technologies in the United States. The company's discovery platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts. Its OmniAb platform is the biological intelligence of proprietary transgenic animals, including OmniRat, OmniChicken, and OmniMouse that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic cand... [Read more]
Financial Performance
In 2023, OmniAb's revenue was $34.16 million, a decrease of -42.17% compared to the previous year's $59.08 million. Losses were -$50.62 million, 126.6% more than in 2022.
Financial StatementsAnalyst Forecast
According to 5 analysts, the average rating for OABI stock is "Strong Buy." The 12-month stock price forecast is $9.2, which is an increase of 70.69% from the latest price.
News
OmniAb Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights
EMERYVILLE, Calif.--(BUSINESS WIRE)--OmniAb, Inc. (NASDAQ: OABI) today reported financial results for the three and 12 months ended December 31, 2023, and provided operating and partner program update...
OmniAb to Report Fourth Quarter 2023 Financial Results on March 20
EMERYVILLE, Calif.--(BUSINESS WIRE)--OmniAb, Inc. (NASDAQ: OABI) will report financial results for the three and 12 months ended December 31, 2023 after the close of the U.S. financial markets on Wedn...
OmniAb to Participate in Two Investor Conferences in March
EMERYVILLE, Calif.--(BUSINESS WIRE)--OmniAb, Inc. (NASDAQ: OABI) today announced that management will be participating in two upcoming investor conferences in March. TD Cowen 44th Annual Healthcare Co...
OmniAb Presents New Scientific Data on its OmnidAb™ Platform at the 2023 Antibody Engineering & Therapeutics Conference
EMERYVILLE, Calif.--(BUSINESS WIRE)--OmniAb, Inc. (Nasdaq: OABI) announces the presentation of new scientific data on its OmnidAb™ platform, the industry's first and only transgenic chicken host syste...
OmniAb Highlights OmnidAb™ Launch and its Expanding Drug Discovery Platform at Today's Research & Technology Virtual Event
EMERYVILLE, Calif.--(BUSINESS WIRE)---- $OABI #OABI--OmniAb, Inc. (Nasdaq: OABI) held its first Research & Technology virtual event earlier today, during which members of the management team reviewed ...
OmniAb Reports Third Quarter 2023 Financial Results and Business Highlights
EMERYVILLE, Calif.--(BUSINESS WIRE)---- $OABI #Antibody--OmniAb, Inc. (NASDAQ: OABI) today reported financial results for the three and nine months ended September 30, 2023, and provided operating and...
OmniAb to Participate in Two Investor Conferences in November
EMERYVILLE, Calif.--(BUSINESS WIRE)---- $OABI #OABI--OmniAb, Inc. (NASDAQ: OABI) today announced that management will be participating in two upcoming investor conferences in November. Stifel 2023 Hea...
OmniAb Appoints Steve Love to its Board of Directors
EMERYVILLE, Calif.--(BUSINESS WIRE)---- $OABI #OABI--OmniAb, Inc. (NASDAQ: OABI) today announced the appointment of Steve Love to its Board of Directors. Mr. Love has more than 30 years of financial e...
OmniAb Announces Agenda for its Research & Technology Virtual Event
EMERYVILLE, Calif.--(BUSINESS WIRE)---- $OABI #OABI--OmniAb, Inc. (Nasdaq: OABI) announces the agenda for its Research & Technology virtual event to be held on Thursday, November 9th beginning at 11:0...
OmniAb to Hold Research & Technology Virtual Event on November 9
EMERYVILLE, Calif.--(BUSINESS WIRE)---- $OABI #Antibody--OmniAb, Inc. (Nasdaq: OABI) today announced it will hold a virtual Research & Technology event on Thursday, November 9 beginning at 11:00 a.m. ...
OmniAb to Participate in Two Investor Conferences in September
EMERYVILLE, Calif.--(BUSINESS WIRE)--OmniAb, Inc. (NASDAQ: OABI) today announced that management will be participating in two upcoming investor conferences in September. H.C. Wainwright 25th Annual Gl...
OmniAb Reports Second Quarter 2023 Financial Results and Business Highlights
EMERYVILLE, Calif.--(BUSINESS WIRE)---- $OABI #OABI--OmniAb, Inc. (NASDAQ: OABI) today reported financial results for the three and six months ended June 30, 2023, and provided operating and partner p...
OmniAb Announces the Passing of Director Sunil Patel
EMERYVILLE, Calif.--(BUSINESS WIRE)-- #OABI--OmniAb, Inc. (NASDAQ: OABI) announces that Director Sunil Patel passed away suddenly last week. The Board of Directors and leadership of OmniAb extend thei...
OmniAb to Report Second Quarter 2023 Financial Results on August 10
EMERYVILLE, Calif.--(BUSINESS WIRE)---- $OABI #OABI--OmniAb, Inc. (Nasdaq: OABI) will report financial results for the three and six months ended June 30, 2023 after the close of the U.S. financial ma...
OmniAb Launches OmniDeep™ at the PEGS Boston Conference and Expo
EMERYVILLE, Calif.--(BUSINESS WIRE)--OmniAb, Inc. (NASDAQ: OABI) announced the launch of OmniDeep™ at the 19th Annual PEGS Boston Conference and Expo: The Essential Protein Engineering & Cell Therapy ...
OmniAb Reports First Quarter 2023 Financial Results and Business Highlights
EMERYVILLE, Calif.--(BUSINESS WIRE)--OmniAb, Inc. (NASDAQ: OABI) today reported financial results for the three months ended March 31, 2023, and provided operating and partner program updates. “Our fi...
OmniAb to Report First Quarter 2023 Financial Results on May 11
EMERYVILLE, Calif.--(BUSINESS WIRE)--OmniAb, Inc. (Nasdaq: OABI) will report financial results for the three months ended March 31, 2023 before the open of the U.S. financial markets on Thursday, May ...
OmniAb to Participate in Upcoming Investor Conferences in May
EMERYVILLE, Calif.--(BUSINESS WIRE)--OmniAb, Inc. (NASDAQ: OABI) today announced that management will be participating in five upcoming investor conferences in May. H.C. Wainwright BioConnect Investor...
OmniAb Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights
EMERYVILLE, Calif.--(BUSINESS WIRE)--OmniAb, Inc. (NASDAQ: OABI) today reported financial results for the three and 12 months ended December 31, 2022, and provided operating and partner program update...
OmniAb to Report Fourth Quarter 2022 Financial Results on March 30
EMERYVILLE, Calif.--(BUSINESS WIRE)--OmniAb, Inc. (NASDAQ: OABI) will report financial results for the three and 12 months ended December 31, 2022 after the close of the U.S. financial markets on Thur...
OmniAb to Participate in Three Upcoming Investor Conferences
OmniAb to Participate in Three Upcoming Investor Conferences
OmniAb Reports Third Quarter 2022 Financial Results and Business Highlights
EMERYVILLE, Calif.--(BUSINESS WIRE)--OmniAb, Inc. (NASDAQ: OABI) reported financial results for the three and nine months ended September 30, 2022 and provided operating and program updates. OmniAb ...
OmniAb to Participate in Two Upcoming Investor Conferences
EMERYVILLE, Calif.
OmniAb Announces Completion of Spin-Off and Business Combination
EMERYVILLE, Calif.